IQ-AI subsidiary applies to FDA for ‘breakthrough therapy'

• click to rate

  Posted by Two Blokes May 2 - Filed in Stock - 3 views
  
  IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) told investors that its wholly owned subsidiary, Imaging Biometrics, has submitted an application to the US Food and Drug Administration (FDA) for Breakthrough Therapy Designation. The application is for its oral gallium maltolate therapy, for treating adult patients with a certain kind of brain tumour (recurrent or refractory glioblastoma IDH-wildtype).